|
NEXMED ANNOUNCES
COMPLETION OF PATIENT ENROLLMENT
IN TWO PIVOTAL PHASE 3 STUDIES
FOR ANTI-FUNGAL PRODUCT
|
|
East
Windsor, NJ, July 9, 2007
-- NexMed, Inc. (NASDAQ: NEXM),
a developer of innovative transdermal
treatments based on the NexACT
drug delivery technology, today
announced that Novartis Pharma
AG has completed patient enrollment
for Phase III clinical trials
for NM100060, a topical treatment
for onychomycosis (nail fungus).
Pursuant to the terms of the
licensing agreement with Novartis,
NexMed will be entitled to a
milestone payment early next
year. NexMed entered into an
exclusive, worldwide agreement
with Novartis in September 2005,
under which Novartis assumed
all clinical development, regulatory,
manufacturing and commercialization
responsibilities for NM100060.
NM100060 is a topical application
of Lamisil® (terbinafine),
formulated with terbinafine
and the Company's patented NexACT
permeation enhancer, which facilitates
the delivery of the drug into
the nail bed, where the fungus
resides.
|
|
|
|
| About NexMed,
Inc. |
|
| NexMed, Inc. is an emerging
drug developer that is leveraging
its proprietary drug technology
to develop a significant pipeline
of innovative pharmaceutical products
to address significant unmet medical
needs. The Company is also working
with various pharmaceutical companies
to explore the incorporation of
NexACT into their existing drugs
as a means of developing new patient-friendly
transdermal products and extending
patent lifespans and brand equity. |
|
|
|
|
